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Background Patients with connective tissue disease-
associated pulmonary arterial hypertension (CTD-PAH), in
particular systemic sclerosis (SSc), had an attenuated
response compared with idiopathic PAH in most trials.
Thus, there is uncertainty regarding the benefit of
PAH-targeted therapy in some forms of CTD-PAH.
Objective To explore the safety and efficacy of initial
combination therapy with ambrisentan and tadalafil
versus ambrisentan or tadalafil monotherapy in patients
with CTD-PAH and SSc-PAH enrolled in the AMBITION
trial.
Methods This was a post hoc analysis of patients with
CTD-PAH and SSc-PAH from AMBITION, an event-driven,
double-blind trial in patients with WHO functional class II/
III PAH. Treatment-naive patients were randomised 2:1:1 to
once-daily initial combination therapy with ambrisentan
plus tadalafil or monotherapy with ambrisentan or
tadalafil, respectively. The primary endpoint was time to
the first clinical failure event (first occurrence of death,
hospitalisation for worsening PAH, disease progression or
unsatisfactory long-term clinical response).
Results In the primary analysis set (N=500), 187
patients had CTD-PAH, of whom 118 had SSc-PAH. Initial
combination therapy reduced the risk of clinical failure
versus pooled monotherapy in each subgroup: CTD-PAH
(HR 0.43 (95% CI 0.24 to 0.77)) and SSc-PAH (0.44 (0.22
to 0.89)). The most common AE was peripheral oedema,
which was reported more frequently with initial
combination therapy than monotherapy in the two PAH
subgroups. The relative frequency of adverse events
between those on combination therapy versus
monotherapy was similar across subgroups.
Conclusions This post hoc subgroup analysis provides
evidence that CTD-PAH and SSc-PAH patients benefit from
initial ambrisentan and tadalafil combination therapy.
Trial registration number NCT01178073, post results.
INTRODUCTION
The main aetiological subgroups in all pivotal
therapeutic trials for pulmonary arterial hyperten-
sion (PAH) have been idiopathic PAH (iPAH) and
connective tissue disease-associated PAH
(CTD-PAH); within the CTD-PAH population, sys-
temic sclerosis (SSc)-associated PAH (SSc-PAH) has
been the leading cause.1–4 In short-term monother-
apy clinical trials using prostanoids,1 5 6 endothelin
receptor antagonists2 7 and phosphodiesterase type
5 (PDE5) inhibitors,3 8 the CTD population
appeared to have an attenuated response to
PAH-targeted therapy compared with patients with
iPAH, particularly when assessed by 6-min walking
distance (6MWD). The results from longer-term
event-driven trials, SERAPHIN9 and GRIPHON10
where the majority of patients received combi-
nation therapy, indicate that CTD-PAH has a similar
reduction in the risk of an event as patients with
iPAH, though no breakdown for SSc-PAH is given
in either trial. A recent meta-analysis comparing
the response to treatment in iPAH and CTD-PAH
concluded that the treatment of CTD-PAH was less
effective than that of iPAH in terms of both
increasing 6MWD and reducing the occurrence of
clinical worsening.11
Observational data in patients with SSc-PAH indi-
cate that survival also appears reduced compared
with iPAH despite more modest haemodynamic dys-
function.12 By contrast, non-SSc-CTD-PAH patients
exhibit similar survival curves to patients with iPAH
when receiving PAH-targeted therapy.13
The attenuated response, particularly in the
short-term trials, has led to suggestions that
6MWD testing may not be an appropriate endpoint
for patients with SSc-PAH.14 An increased preva-
lence of veno-occlusive disease,15 occult left heart
involvement,16 associated lung disease17 and mus-
culoskeletal involvement14 in patients labelled as
having SSc-PAH are proposed as potential explana-
tions for the apparent attenuated response.
The AMBITION trial, previously reported, was a
phase III/IV, randomised, double-blind, event-driven
trial comparing the safety and efficacy of ambrisen-
tan and tadalafil initial combination therapy to
ambrisentan or tadalafil monotherapy in treatment-
naive patients with WHO/New York Heart
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Association functional class II or III PAH.18 AMBITION
included a sizable population with CTD-PAH, thus providing an
opportunity to evaluate the response to initial combination
therapy versus monotherapy in a long-term, event-driven study.
We present a post hoc analysis of the CTD-PAH population,
as well as the SSc subset of the CTD group. In addition, we
provide data on the patients with iPAH/heritable PAH (hPAH)
from the AMBITION study to explore if there are different
responses to treatment between the PAH aetiologies.
METHODS
Study design and oversight
This was a post hoc subgroup analysis of the AMBITION trial
that has been previously described in detail.18 Randomisation
was performed centrally using an interactive voice response
system. Eligible patients were stratified based on underlying aeti-
ology of PAH (iPAH/hPAH vs non-iPAH) and WHO functional
class (II vs III). Within both strata, patients were randomised
2:1:1 to initial combination therapy (ambrisentan 10 mg plus
tadalafil 40 mg) or to monotherapy (ambrisentan 10 mg plus
placebo or tadalafil 40 mg plus placebo).
Monitoring and data collection were overseen by the spon-
sors. All reported clinical events were adjudicated by an inde-
pendent clinical endpoint committee that was blinded to
treatment randomisation and investigator. Statistical analyses
were performed by Hartington Statistics and Data Management
and were overseen by the sponsors.
Patients
Patients were aged 18–75 years, weighed ≥40 kg and had base-
line WHO functional class II or III symptoms and a diagnosis of
iPAH, hPAH, CTD-PAH or PAH associated with drugs or
toxins, HIV (stable disease status) or repaired congenital heart
defects. Further, all patients were required to have a total lung
capacity ≥60% of predicted normal, a forced expiratory volume
in 1 s ≥55% of predicted normal, and at the start of enrolment,
a mean pulmonary artery pressure ≥25 mm Hg, a pulmonary
capillary wedge pressure (PCWP) or left ventricular end dia-
stolic pressure (LVEDP) ≤15 mm Hg and a pulmonary vascular
resistance (PVR) ≥240 dyne·s/cm5.
After 6 months of study enrolment, a blinded review of the
participants’ baseline demographic data revealed a relatively
high prevalence of risk factors for left ventricular diastolic dys-
function. Therefore, the eligibility criteria were amended to
include more rigorous haemodynamic requirements (PVR
increased from ≥240 to ≥300 dyne·s/cm5 for all patients; for
patients with a PVR ≥300 to <500 dyne·s/cm5, a PCWP or
LVEDP ≤12 mm Hg; and for those with a PVR ≥500 dyne·s/
cm5, a PCWP ≤15 mm Hg) and to exclude patients with ≥3 of
the following risk factors for left ventricular diastolic dysfunc-
tion: body mass index ≥30 kg/m2, history of essential hyperten-
sion, diabetes mellitus and historical evidence of significant
coronary artery disease. The primary analysis set (PAS) com-
prised the patients who fulfilled the amended inclusion criteria.
Assessments
The primary endpoint was the time from randomisation to first
adjudicated clinical failure, defined as the first occurrence of
death, hospitalisation for worsening PAH (any hospitalisation
for worsening PAH, lung or heart/lung transplant, atrial septost-
omy or initiation of parenteral prostanoid therapy), disease pro-
gression (decrease of >15% from baseline 6MWD combined
with WHO functional class III or IV symptoms at two consecu-
tive visits separated by ≥14 days) or unsatisfactory long-term
clinical response (any decrease from baseline 6MWD at two
consecutive postbaseline clinic visits separated by ≥14 days and
WHO functional class III symptoms assessed at two clinic visits
separated by ≥6 months). The time to first occurrence of each
of the individual components of the primary endpoint was also
analysed.
Secondary endpoints included change from baseline at week
24 in N-terminal pro-B-type natriuretic peptide (NT-proBNP)
level, satisfactory clinical response to therapy (10% improve-
ment in 6MWD compared with baseline, with improvement to
or maintenance of WHO functional class I or II symptoms, and
no events of clinical worsening before or at the week 24 visit),
6MWD, Borg dyspnoea index and WHO functional class.
Safety endpoints included adverse events (AEs) and laboratory
assessments.
Efficacy and safety assessments were performed at screening
and randomisation visits; at weeks 4, 8, 16, 24 and every
12 weeks thereafter; at the final assessment visit; and at the
end-of-study visit. Laboratory assessments were performed
monthly.
Statistical analyses
The PAS included all randomised patients who received study
drug and met the amended entry criteria. Analyses are presented
by diagnosis of PAH; because these subgroup analyses are post
hoc, p values are not presented. The Kaplan-Meier product
limit method was used to generate survival curves for time from
randomisation to first adjudicated clinical failure. Cox
proportional-hazards regression models were used to calculate
the HR and 95% CI. NT-proBNP levels are presented as the
geometric mean and geometric mean ratio and were analysed
using mixed models repeated measures. The percentage of
patients with a satisfactory clinical response was analysed as a
binary endpoint using logistic regression, with no imputation
for missing values. 6MWD was analysed using the stratified
Wilcoxon rank-sum test; missing values were imputed using last
observation carried forward or worst rank scores for missing
data following death or adjudicated hospitalisation for PAH.
Among patients recorded as having ‘other’ forms of
CTD-PAH, 12 of 26 were further described as having CREST
syndrome (calcinosis cutis, Raynaud’s phenomenon, oesopha-
geal dysfunction, sclerodactyly and telangiectasias), or limited or
diffuse cutaneous SSc. To explore the possibility that misclassifi-
cation of these patients led to a bias in favour of a treatment
effect in the SSc-PAH population, a sensitivity analysis on the
primary endpoint was performed where these patients were
assigned to the SSc-PAH population.
RESULTS
A total of 187 of 500 patients in the PAS had CTD-PAH, and
slightly more than half (n=103) of patients with CTD-PAH,
were randomised to initial combination therapy and 84 to
pooled monotherapy. SSc-PAH comprised 63% (118/187) of
the CTD-PAH population. Figure 1 shows the distribution of
this population among the treatment arms, and table 1 the full
breakdown of CTD sub-aetiologies.
Among patients with CTD-PAH, those in the SSc-PAH subset
tended to be older than the non-SSc-PAH population (mean
61.5 vs 52.6 years). Haemodynamic severity of disease at diag-
nosis was similar between the SSc-PAH subset and the
non-SSc-PAH population. Baseline characteristics in patients
randomised to combination therapy compared with pooled
monotherapy were generally well balanced, though some differ-
ences were seen in the SSc-PAH group, where those randomised
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to combination therapy had a lower 6MWD, higher
NT-proBNP level and a lower use of immunosuppressants. No
additional obvious differences were observed between the com-
bination therapy arm and each of the individual monotherapy
arms. Table 2 summarises baseline characteristics and haemo-
dynamics for the CTD-PAH and SSc-PAH populations, and
online supplementary table S1 provides the same data for
SSc-PAH and non-SSc-CTD patients.
Primary endpoint
Among patients randomised to initial combination therapy, the
risk of experiencing a first clinical failure event in the popula-
tion with CTD-PAH was reduced compared with those on
initial monotherapy with HRs of 0.43 (95% CI 0.24 to 0.77)
versus pooled monotherapy (figure 2A), 0.51 (95% CI 0.25 to
1.01) versus ambrisentan monotherapy and 0.40 (95% CI 0.20
to 0.77) versus tadalafil monotherapy. The HRs correspond to
risk reductions of 57%, 49% and 60%, respectively. The magni-
tude of benefit of combination therapy over monotherapy was
similar in the SSc-PAH population with HRs of 0.44 (95% CI
0.22 to 0.89) versus pooled monotherapy (figure 2B), 0.52
(95% CI 0.21 to 1.26) versus ambrisentan monotherapy and
0.44 (95% CI 0.20 to 0.97) versus tadalafil monotherapy. The
HRs correspond to risk reductions of 56%, 48% and 56%,
respectively.
Overall in CTD-PAH, 19% (20/103) of combination therapy
patients experienced a primary endpoint event and 36% (30/84)
of monotherapy patients experienced a primary endpoint event;
in SSc-PAH, it was 21% (15/71) of combination therapy and
40% (19/47) of monotherapy patients.
The results for the time to first occurrence of the four indi-
vidual components of the primary endpoint by PAH type, along
Figure 1 Flow chart of population
distribution among the treatment
arms. The modified intention-to-treat
(mITT) population includes patients
who were randomised and received
study drug. The ex-primary analysis set
(PAS) population includes patients who
were randomised and received study
drug but did not meet the amended
entry criteria. The PAS population
includes patients who were
randomised, received study drug, and
met the amended entry criteria. The
last row of this figure is a post hoc
summary. CTD, connective tissue
disease; FAV, final assessment visit;
PAH, pulmonary arterial hypertension;
SSc, systemic sclerosis.














52 (50) 30 (36) 17 (39) 13 (33) 82 (44)
Diffuse cutaneous systemic
sclerosis
19 (18) 17 (20) 6 (14) 11 (28) 36 (19)
Mixed connective tissue
disease
11 (11) 12 (14) 3 (7) 9 (23) 23 (12)
Systemic lupus erythematosus 11 (11) 6 (7) 5 (11) 1 (3) 17 (9)
Overlap syndrome 2 (2) 1 (1) 0 1 (3) 3 (2)
Other 8 (8) 18 (21) 13 (30) 5 (13) 26 (14)
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with an analysis of time to clinical worsening (where the unsatis-
factory long-term clinical response component is removed from
the composite endpoint), are presented in figure 3. Time to first
hospitalisation for worsening PAH showed the greatest differ-
ence between combination therapy and monotherapy for both
the overall CTD-PAH population (risk reduction: 71%; HR
0.29 (95% CI 0.12 to 0.67)) and the SSc-PAH population (risk
reduction: 64%; HR 0.36 (95% CI 0.13 to 1.04)).
Sensitivity analysis
In the sensitivity analysis, patients classified as other-CTD-PAH
on the case report form but further described as having
SSc-PAH were included, increasing the number of patients in
the SSc-PAH subset from 118 to 130. Of these, 75 patients
received initial combination therapy and 55 were randomised to
monotherapy. The HR for the primary endpoint sensitivity ana-
lysis was 0.47 (95% CI 0.24 to 0.92), corresponding to a 53%
risk reduction and indicating that any misclassification had little
impact on the reported outcomes.
Secondary endpoints
At week 24, mean reduction in NT-proBNP from baseline was
consistent between diagnosis subgroups and greater in patients
receiving combination therapy versus pooled monotherapy:
overall CTD-PAH (−60.4% vs −43.1%) and SSc-PAH (−62.8%
vs −38.4%). The corresponding geometric mean ratios
expressed as % differences were −30.4% (95% CI −49.0 to
−5.2) and −39.6% (95% CI −59.3 to −10.2) for the two
populations, respectively. Rates of satisfactory clinical response
at week 24 were similar with combination therapy and pooled
monotherapy in the overall CTD-PAH (35% combination, 29%
monotherapy; OR 1.321 (95% CI 0.680 to 2.565)) and
SSc-PAH populations (31% combination, 29% monotherapy;
OR 1.111 (95% CI 0.474 to 2.604)). A greater increase in
median 6MWD from baseline was seen at week 24 in patients
receiving initial combination therapy versus pooled monother-
apy in the overall CTD-PAH (+42.0 vs +24.3 m) and SSc-PAH
(+40.9 vs +12.2 m) populations. The corresponding median
differences (combination—monotherapy) were +19.7 m (95%
CI +1.0 to +38.4) and +30.3 m (95% CI +4.0 to +56.5) for
the two populations, respectively. In a post hoc analysis, the
proportion of patients with a ≥15% decrease in 6MWD at any
time post baseline was greater with pooled monotherapy
than with combination therapy across all subgroups (CTD-
PAH, SSc-PAH and non-SSc-PAH) (see online supplementary
table S2).
Safety
Post hoc summaries indicate that patients with CTD-PAH were
treated for a mean (SD) of 584 (356) days in the combination
therapy arm and 499 (329) days in the pooled monotherapy
arm, and patients with SSc-PAH were treated for 566 (363) days
and 504 (330) days, respectively. No new safety signal was iden-
tified in the overall CTD-PAH or SSc-PAH populations. The
most common AEs (≥25%) in the combination therapy group
for these two populations were peripheral oedema (47%













Median (Q1, Q3) time from diagnosis to study drug
administration (days)
20 (8, 49) 21.5 (8, 49) 20 (8, 45) 16 (8, 35)
Mean (SD) age (years) 58.4 (12.3) 57.9 (13.1) 62.0 (9.2) 60.7 (10.7)
Sex, n (%)
Female 89 (86) 76 (90) 58 (82) 41 (87)
Male 14 (14) 8 (10) 13 (18) 6 (13)
WHO functional class, n (%)
II 26 (25) 22 (26) 16 (23) 11 (23)
III 77 (75) 62 (74) 55 (77) 36 (77)
6-min walk distance (m)
Mean (SD) 324.8 (86.3) 327.9 (98.0) 312.8 (87.7) 328.9 (98.2)
Median 333.1 346.8 313.2 352.0
Median (Q1, Q3) NT-proBNP (ng/L) 1321 (372, 2995) n=98 1128 (337, 2357) n=82 1713 (332, 3294) n=68 1152 (382, 2576) n=46
Mean (SD) % of predicted normal TLC 89.0 (15.7) n=102 88.6 (17.6) n=83 89.8 (16.4) n=70 90.0 (18.4)
Mean (SD) % of predicted normal FEV1 84.3 (18.8) 81.4 (16.4) 86.2 (19.8) 85.9 (17.4)
Prior medications, n (%)
Immunosuppressants 14 (14) 13 (15) 4 (6) 5 (11)
Steroids 18 (17) 17 (20) 10 (14) 7 (15)
Mean (SD) mean right atrial pressure (mm Hg) 7.4 (4.2) n=102 7.7 (4.5) 7.4 (4.2) 7.6 (4.7)
Mean (SD) cardiac index (L/min/m2) 2.55 (0.63) 2.67 (0.73) n=83 2.57 (0.60) 2.54 (0.62) n=46
Mean (SD) mean pulmonary arterial pressure (mm Hg) 43.5 (10.4) 45.1 (10.0) 43.7 (10.3) 45.7 (10.1)
Mean (SD) pulmonary capillary wedge pressure
(mm Hg)
8.2 (3.0) n=102 9.1 (3.3) n=82 8.3 (3.0) 8.6 (3.3) n=45
Mean (SD) pulmonary vascular resistance (dyne·s/cm5) 672.3 (274.5) 667.1 (257.8) 674.7 (267.8) 702.2 (265.3)
Post hoc summary.
CTD, connective tissue disease; FEV1, forced expiratory volume in 1 s; NT-proBNP, N-terminal pro-B-type natriuretic peptide; PAH, pulmonary arterial hypertension; Q1, quartile 1; Q3,
quartile 3; SSc, systemic sclerosis; TLC, total lung capacity.
4 Coghlan JG, et al. Ann Rheum Dis 2016;0:1–9. doi:10.1136/annrheumdis-2016-210236
Clinical and epidemiological research









is: first published as 10.1136/annrheum






combination, 34% ambrisentan and 33% tadalafil in CTD-PAH;
45%, 26% and 33%, respectively, in SSc-PAH), headache (33%
combination, 32% ambrisentan and 38% tadalafil in CTD-PAH;
28%, 26% and 33%, respectively, in SSc-PAH) and diarrhoea
(29% combination, 32% ambrisentan and 25% tadalafil in
CTD-PAH; 28%, 17% and 29%, respectively, in SSc-PAH).
Anaemia occurred at a similar incidence in the combination
therapy and tadalafil monotherapy groups, but was not reported
in the ambrisentan monotherapy group (19% combination, 0%
ambrisentan and 15% tadalafil in CTD-PAH; 21%, 0% and
17%, respectively, in SSc-PAH). Overall rates of serious adverse
events (SAEs) and AEs leading to permanent discontinuation of
study drug were similar in the overall CTD-PAH and SSc-PAH
populations, with no trend towards an excess of such events
with initial combination therapy compared with monotherapy
(table 3). In patients with CTD-PAH, SAE rates were 44% with
combination therapy, 34% with ambrisentan monotherapy and
50% with tadalafil monotherapy. SAE rates were similar in
patients with SSc-PAH (44%, 39% and 58%, respectively).
Comparison with the iPAH/hPAH subgroup
Baseline characteristics indicated some similarities and differ-
ences between patients in the iPAH/hPAH subgroup and those
in the CTD-PAH and SSc-PAH subgroups. Patients with
iPAH/hPAH had similar functional status, but they were, on
average, younger and had a longer 6MWD, lower NT-proBNP
level and worse haemodynamics (see online supplementary table
S3). Results for the primary endpoint (see online supplementary
figure S1) and individual components of the primary endpoint
(see online supplementary figure S2) were similar in the iPAH/
hPAH population compared with the CTD-PAH and SSc-PAH
populations. For the primary endpoint in the iPAH/hPAH popu-
lation, initial combination therapy reduced the risk of experien-
cing a first clinical failure event compared with initial
monotherapy (risk reduction: 49%; HR 0.51 (95% CI 0.31 to
0.83)). Overall, in patients with iPAH/hPAH 19% (25/134) of
the combination group and 32% (46/145) of the monotherapy
group experienced a primary endpoint event. Among the sec-
ondary endpoints in the patients with iPAH/hPAH, mean
change in NT-proBNP from baseline at week 24 was −71.2%
with combination therapy and −50.0% with pooled monother-
apy; geometric mean ratio expressed as percentage difference
was −42.5% (95% CI −54.6 to −27.0). Compared with pooled
monotherapy, combination therapy was associated with a
greater proportion of patients with a satisfactory clinical
response at week 24 (40% vs 28%, OR 1.736 (95% CI 1.035
to 2.911)) and a greater increase in median 6MWD from base-
line at week 24 (+52.5 vs +26.6 m). The corresponding
median difference was +26.6 m (95% CI +11.6 to +41.5).
Among patients with iPAH/hPAH, AEs occurring in ≥25% on
initial combination therapy were peripheral oedema (48% com-
bination vs 31% ambrisentan and 27% tadalafil) and headache
(45% vs 32% and 31%, respectively). Other AEs as well as rates
of SAEs and AEs leading to permanent discontinuation of study
drug were more evenly distributed among treatment groups.
Rates of SAEs and AEs leading to permanent discontinuation of
Figure 2 Kaplan-Meier curves for the
time from randomisation to first
adjudicated clinical failure in the (A)
connective tissue disease-associated
pulmonary arterial hypertension
population and (B) systemic
sclerosis-pulmonary arterial
hypertension population. Post hoc
figures. The HR is for combination
versus pooled monotherapy.
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study drug were lower in the iPAH/hPAH population (see online
supplementary table S4) compared with the CTD-PAH and
SSc-PAH populations. In patients with iPAH/hPAH, rates of
SAEs were 33% with combination therapy, 37% with ambrisen-
tan monotherapy and 39% with tadalafil monotherapy, and
rates of AEs leading to permanent discontinuation of study drug
were 11%, 8% and 11%, respectively.
DISCUSSION
The AMBITION trial included a sizable number of patients
with CTD-PAH, and within this SSc-PAH, and thus provides an
opportunity to explore whether this population responds to
initial combination therapy with ambrisentan and tadalafil com-
pared with monotherapy of either agent. Initial combination
therapy resulted in a reduction in the risk of clinical failure
versus pooled monotherapy of 57% in patients with CTD-PAH
and 56% in the subset of patients with SSc-PAH. While inferen-
tial statistics are not presented, the 95% CIs around the HR for
both CTD-PAH and SSc-PAH were well within the bounds of
0–1. This result is further supported by the secondary end-
points, where we see a greater improvement in plasma
NT-proBNP levels and 6MWD on combination therapy com-
pared with monotherapy. The benefit of combination therapy
over monotherapy is of similar magnitude to that observed in
the whole trial population.
No new safety signals were identified in the CTD-PAH subset.
However, some AEs appeared to be more frequent in CTD-PAH
than in the iPAH/hPAH population (eg, diarrhoea and anaemia),
possibly due to coexisting connective tissue disease.
This subgroup analysis offers a number of insights that are
informative to the management of patients with CTD-PAH. As
previously reported, patients with CTD-PAH tend to have more
modest haemodynamic dysfunction than patients with iPAH/
hPAH, though do not appear to have a better outcome. It has
been reported that the CTD-PAH population, particularly
SSc-PAH, has a relatively poor prognosis, and their response to
PAH-targeted monotherapies in short-term trials (eg, reduction
of clinical worsening events, improvements in exercise ability)
Figure 3 Forest plot of time to first occurrence of clinical failure, clinical worsening, death, hospitalisation, disease progression and unsatisfactory
long-term clinical response (ULTCR) in the (A) connective tissue disease-associated pulmonary arterial hypertension population and (B) systemic
sclerosis-pulmonary arterial hypertension population. Post hoc figures. The HR is for combination versus pooled monotherapy.
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has, with the exception of the initial epoprostenol trial,19 not
been as robust as in the iPAH/hPAH population.
The present findings in the monotherapy arm support this,
with 32% of patients with iPAH/hPAH, 36% of patients with
CTD-PAH and 40% of patients with SSc-PAH experiencing a
clinical failure event. However, the combination therapy arm of
iPAH/hPAH, CTD-PAH and SSc-PAH had an overall incidence
of a clinical failure event of 19%, 19% and 21%, respectively.
This corresponds to a risk reduction for combination therapy of
49% in iPAH/hPAH, 57% in CTD-PAH and 56% in SSc-PAH
compared with pooled monotherapy, suggesting that initial oral
combination therapy in the CTD-PAH population may result in
similar outcomes to that observed in the iPAH/hPAH patient
group, at least over the duration of this study.
This is supported by the results of the 6MWD, particularly
for SSc-PAH, where monotherapy provided a limited improve-
ment from baseline over 24 weeks (12.2 m), which is in line
with the previous short-term monotherapy trials. However,
initial combination therapy resulted in a 40.9 m improvement
from baseline, indicating perhaps that the 6MWD may not be
an inappropriate endpoint in patients with SSc-PAH and may be
a useful indicator of response to treatment.
Additionally, a 15% worsening of 6MWD has been associated
with a significantly worse prognosis in the REVEAL study.20 In
AMBITION, the number of subjects with a ≥15% worsening at
any time was 31/131 (24%) with combination therapy com-
pared with 46/144 (32%) with monotherapy in the iPAH/hPAH
group and similarly was 21/67 (31%) on combination therapy
compared with 20/45 (44%) on monotherapy in the SSc-PAH
group over the course of this long-term study (see online
supplementary table S2).
These results support the notion that CTD-PAH, particularly
SSc-PAH, may need a more aggressive treatment regimen to see
similar benefits to patients with iPAH.
In AMBITION, a protocol amendment was made to allow for
a more rigorous approach of excluding postcapillary pulmonary
venous hypertension from the PAS population,18 which may
have provided a possible explanation for the results. However,
an analysis of the modified intent-to-treat population (all rando-
mised patients who received study drug), which includes a
further 29 patients with CTD-PAH (19 of whom were
SSc-PAH), shows similar results, with risk reductions of 52% for
CTD-PAH (HR 0.48; 95% CI 0.29 to 0.82) and 54% for
SSc-PAH (HR 0.46; 95% CI 0.24 to 0.90), indicating that
excluding patients who failed to meet the revised inclusion cri-
teria had limited impact on the outcome. Other eligibility cri-
teria, including pulmonary function parameters, remained
unchanged and in line with other PAH trials. The purpose of
the pulmonary function test (PFT) parameters is to exclude
those patients whose PH was likely driven by lung disease.
However, such restrictions would not remove the possibility of
including patients with a modest degree of pulmonary fibrosis
or exclude the possibility of pulmonary veno-occlusive disease
in the CTD-PAH population.
Our data are supported by a recent study published by
Hassoun and colleagues.21 In this open-label study of 24















Any AE* 102 (99) 42 (95) 39 (98) 70 (99) 22 (96) 23 (96)
Oedema peripheral 48 (47) 15 (34) 13 (33) 32 (45) 6 (26) 8 (33)
Headache 34 (33) 14 (32) 15 (38) 20 (28) 6 (26) 8 (33)
Diarrhoea 30 (29) 14 (32) 10 (25) 20 (28) 4 (17) 7 (29)
Dyspnoea 23 (22) 9 (20) 10 (25) 18 (25) 2 (9) 6 (25)
Serious AEs† 45 (44) 15 (34) 20 (50) 31 (44) 9 (39) 14 (58)
Pulmonary hypertension‡ 7 (7) 3 (7) 6 (15) 4 (6) 0 5 (21)
Pneumonia 6 (6) 3 (7) 2 (5) 3 (4) 3 (13) 1 (4)
Dyspnoea 4 (4) 2 (5) 2 (5) 4 (6) 1 (4) 2 (8)
Anaemia 3 (3) 0 3 (8) 3 (4) 0 1 (4)
Syncope 2 (2) 1 (2) 1 (3) 0 0 0
AEs leading to permanent study drug
discontinuation§
14 (14) 8 (18) 6 (15) 10 (14) 3 (13) 3 (13)
Oedema peripheral 2 (2) 3 (7) 1 (3) 2 (3) 2 (9) 0
Diarrhoea 2 (2) 0 0 1 (1) 0 0
Nausea 2 (2) 0 0 2 (3) 0 0
Headache 2 (2) 0 0 1 (1) 0 0
Dyspnoea 1 (<1) 0 0 1 (1) 0 0
Pulmonary oedema 0 1 (2) 0 0 1 (4) 0
Post hoc summary.
*AEs occurring in ≥25% of patients on combination therapy in either the CTD-PAH or SSc-PAH populations.
†SAEs occurring in ≥4% of patients on combination therapy in either the CTD-PAH or SSc-PAH populations; only the iPAH/hPAH population met this criterion for syncope (after rounding)
(see online supplementary table S4), but rates are shown in this table to allow for comparison.
‡In each case, the investigator reported the events using additional text not captured in the preferred term, describing this as worsening of pulmonary hypertension. However, an AE
report of worsening pulmonary hypertension does not necessarily become a primary endpoint event, which has specific criteria.
§AEs leading to permanent study drug discontinuation in ≥2 patients on combination therapy in either the CTD-PAH or SSc-PAH populations; only the iPAH/hPAH population met this
criterion for dyspnoea and pulmonary oedema (see online supplementary table S4), but rates are shown in this table to allow for comparison.
AE, adverse event; AMB, ambrisentan; COMB, combination therapy; CTD, connective tissue disease; hPAH, heritable pulmonary arterial hypertension; iPAH, idiopathic pulmonary arterial
hypertension; Mono, monotherapy; PAH, pulmonary arterial hypertension; SAE, serious adverse event; SSc, systemic sclerosis; TAD, tadalafil.
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treatment-naive patients diagnosed with SSc-PAH, the initiation
of treatment with ambrisentan (10 mg) and tadalafil (40 mg)
daily for 36 weeks resulted in a statistically significant improve-
ment from baseline in the co-primary endpoint of reduction in
right ventricular mass and PVR. There were also significant
improvements in the secondary endpoints, including an estimate
of pulmonary artery compliance (stroke volume/pulmonary
pulse pressure ratio), echo-measured tricuspid annular plane sys-
tolic excursion, 6MWD, functional class and serum NT-proBNP.
The most common AEs included fluid accumulation (29%),
headache (29%) and nasal congestion (16%); SAEs were rare
and limited, and included one case of fluid overload requiring
hospitalisation.
Our study has several limitations. These were post hoc ana-
lyses of the subgroups with CTD-PAH and SSc-PAH. Given the
small number of non-SSc-CTD-PAH patients, no reliable com-
parisons of treatment response between the CTD sub-aetiologies
are possible. Twelve patients were classified as ‘other’ CTD-PAH
when subsequent descriptors suggested that these patients may
have had SSc-PAH; however, a sensitivity analysis showed that
this did not affect the overall findings.
CONCLUSIONS
This post hoc analysis of patients with CTD-PAH in
AMBITION suggests that this subpopulation did at least as well
on initial combination therapy compared with patients with
iPAH/hPAH, both in terms of clinical failure risk reduction and
improvement in exercise ability. There were no new safety signals
observed in the CTD-PAH cohort compared with the full study
results, though rates of SAEs and AEs leading to permanent dis-
continuation of study drug were higher in the CTD-PAH group
than the iPAH/HPAH group. In the CTD-PAH population, an
aggressive approach to treatment with initial combination therapy
may improve outcomes and exercise capacity as opposed to treat-
ment with monotherapy.
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